These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 22363732

  • 21. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA, Iannetta M, Pontecorvo S, Anzivino E, Prezioso C, Rodio DM, Morreale M, D'Abramo A, Oliva A, Lichtner M, Cortese A, Frontoni M, Pietropaolo V, Francia A, Mastroianni CM, Vullo V, Ciardi MR.
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [Abstract] [Full Text] [Related]

  • 22. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T.
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec 17; 11(6):e200321. PubMed ID: 39393045
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 17; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 29. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.
    N Engl J Med; 2009 Sep 10; 361(11):1067-74. PubMed ID: 19741227
    [Abstract] [Full Text] [Related]

  • 30. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
    Mult Scler; 2012 Aug 10; 18(8):1125-34. PubMed ID: 22194217
    [Abstract] [Full Text] [Related]

  • 31. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 10; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 32. Natalizumab and HSV meningitis.
    Shenoy ES, Mylonakis E, Hurtado RM, Venna N.
    J Neurovirol; 2011 Jun 10; 17(3):288-90. PubMed ID: 21487835
    [Abstract] [Full Text] [Related]

  • 33. Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.
    Sottini A, Capra R, Zanotti C, Chiarini M, Serana F, Ricotta D, Caimi L, Imberti L.
    PLoS One; 2012 Jun 10; 7(4):e34493. PubMed ID: 22496817
    [Abstract] [Full Text] [Related]

  • 34. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 10; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 35. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK, McDonald JW.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD006097. PubMed ID: 16856112
    [Abstract] [Full Text] [Related]

  • 36. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
    Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B.
    Front Immunol; 2020 Jul 19; 11():549842. PubMed ID: 33072089
    [Abstract] [Full Text] [Related]

  • 37. Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.
    Proschmann U, Inojosa H, Akgün K, Ziemssen T.
    Front Neurol; 2021 Jul 19; 12():650530. PubMed ID: 33935948
    [Abstract] [Full Text] [Related]

  • 38. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec 19; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 39. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 40. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Dec 15; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.